Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial.

Antroula PapakonstantinouAlexios MatikasNils Olof BengtssonPer MalmströmElham HedayatiGuenther StegerMichael UntchLaila HübbertHemming JohanssonMats HellströmMichael GnantSibylle LoiblRichard GreilVolker MoebusTheodoros FoukakisJonas Bergh

Published in: Cancer (2019)

The combination of DD chemotherapy and trastuzumab decreased the relative risk for relapse by 32% in comparison with standard treatment, a statistically nonsignificant difference. Its efficacy and safety merit further evaluation as part of both escalation and de-escalation strategies.

Keyphrases

positive breast cancer
epidermal growth factor receptor
open label
metastatic breast cancer
clinical trial
study protocol
phase ii
lymph node
randomized controlled trial
combination therapy
free survival
tyrosine kinase
chemotherapy induced